Stephan von Haehling
Stephan von Haehling is an expert in Cardiology at Universitätsmedizin Göttingen (Germany). As of November 2026, ScienceLeadR ranks Stephan von Haehling in the top 1% of experts worldwide for Cachexia, Sarcopenia and Weight Loss. Stephan von Haehling has authored 684 publications, the most recent in 2026, and is an investigator in 29 clinical trials, 4 of them ongoing. SLR score: 2,599 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Pharmacy - Endocrinology - Internal Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2003 - 2026
Number : 684
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Sex-Specific Mechanisms and Therapeutics in Heart Failure: Translating Biology into Personalized Care. PMID 42961949 — fibrosis, heart failure, heart, translating, phenotype, biomarkers, sex characteristics, sex, precision medicine, therapeutics, sex differences | ESC Heart Fail | 2026 | 0 |
| Cardiometabolic therapy for rhythm control: a case report of refractory atrial fibrillation resolving after initiation of semaglutide for obesity. PMID 42877389 — glucagon-like peptide 1, electric countershock, atrial fibrillation, obesity, therapeutics, semaglutide | Eur Heart J Case Rep | 2026 | 0 |
| Gut Microbiota in Heart Failure with Preserved Ejection Fraction: Clinical Phenotyping and Therapeutic Opportunities. PMID 42792863 — genes, heart failure, heart, stress, physiological, heart failure, diastolic, therapeutics, gastrointestinal microbiome, microbiota | Biomedicines | 2026 | 0 |
| Contemporary Evaluation and Management Strategies for Tricuspid Regurgitation. PMID 42683885 — cardiovascular diseases, pulmonary artery, arteries, therapeutics, tricuspid valve insufficiency, hemodynamics | Crit Pathw Cardiol | 2026 | 0 |
| Multimorbidity patterns influence mobility disability prevention in frail older adults from the SPRINTT trial. PMID 42675189 — aging, multimorbidity | Nat Aging | 2026 | 0 |
Clinical Studies 29
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Effects of continued administration of empagliflozin in patients with heart failure on active SGLT2 inhibitor treatment admitted for acute decompensated heart failure 2024-517977-26-00 — sodium-glucose transporter 2 inhibitors, hospitalization, heart failure, heart, therapeutics | Phase 3 | Recruiting | 2025 |
| Cognitive Function Depression Anxiety and Quality of Life in Chronic Heart Failure Patients with Iron Deficiency with and without Anaemia Effects of Intravenous Iron (Ferric Derisomaltose) CogFer HF Study 2024-515046-17-00 — depression, quality of life, anemia, heart failure, heart, cognitive dysfunction, cognition disorders, cognition, iron deficiencies | Phase 4 | Recruiting | 2024 |
| Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure NCT07038356 — sodium-glucose transporter 2 inhibitors, hospitalization, heart failure, heart, tablets, diuretics, therapeutics | Phase 3 | Recruiting | 2025 |
| Dapagliflozin in patients with Right Heart Failure (Dapa RHF) 2024-515044-23-01 — heart failure, heart | Phase 2 | Recruiting | 2024 |
LeadR Networks
Main global connection map